Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 3, 2012, Pages 600-608

  Beinborn, Nicole A ^a   Du, Ju ^a   Wiederhold, Nathan P ^a,b   Smyth, Hugh D C ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antifungal; Inhalation; Lung; Preclinical pharmacokinetics; Pulmonary delivery; Voriconazole

Indexed keywords

EXCIPIENT; INHALAC 70; LACTOSE; NANOMATERIAL; POVIDONE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CRYSTAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; DRY POWDER INSUFFLATION; IMMUNOCOMPROMISED PATIENT; LUNG ASPERGILLOSIS; LUNG PARENCHYMA; LUNG WEIGHT; MALE; MORPHOLOGY; MORTALITY; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; POROSITY; POWDER INHALER; SINGLE DRUG DOSE; THIN FILM FREEZING; X RAY POWDER DIFFRACTION;

ADMINISTRATION, INHALATION; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRYSTALLIZATION; DRY POWDER INHALERS; EXCIPIENTS; FREEZING; LUNG; MALE; MICE; MICE, INBRED ICR; PARTICLE SIZE; POVIDONE; PYRIMIDINES; SOLUBILITY; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84863776903     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.04.019     Document Type: Article

References (45)

1. S.R. Doffman, S.G. Agrawal, J.S. Brown, Invasive pulmonary aspergillosis, Expert Review of Anti-Infective Therapy 3 (2005) 613-627. (Pubitemid 41223221)
2. J.J. Caston-Osorio, A. Rivero, J. Torre-Cisneros, Epidemiology of invasive fungal infection, International Journal of Antimicrobial Agents 32 (Suppl. 2) (2008) S103-S109.
3. M. Cuenca-Estrella, L. Bernal-Martinez, M.J. Buitrago, M.V. Castelli, A. Gomez-Lopez, O. Zaragoza, J.L. Rodriguez-Tudela, Update on the epidemiology and diagnosis of invasive fungal infection, International Journal of Antimicrobial Agents 32 (Suppl. 2) (2008) S143-S147.
4. W. Meersseman, S.J. Vandecasteele, A. Wilmer, E. Verbeken, W.E. Peetermans, E. Van Wijngaerden, Invasive aspergillosis in critically ill patients without malignancy, American Journal of Respiratory and Critical Care Medicine 170 (2004) 621-625. (Pubitemid 39202203)
5. S.J. Roffey, S. Cole, P. Comby, D. Gibson, S.G. Jezequel, A.N.R. Nedderman, D.A. Smith, D.K. Walker, N. Wood, The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human, Drug Metabolism and Disposition 31 (2003) 731-741. (Pubitemid 36617661)
6. FDA, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
7. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, M.G. Ramsey, Solubility and dissolution studies of antifungal drug: hydroxybutenyl-b-cyclodextrin complexes, Cellulose 14 (2007) 35-47. (Pubitemid 46486879)
8. C. Joukhadar, C. Thallinger, W. Poppl, F. Kovar, K.H. Konz, S.M. Joukhadar, F. Traunmuller, Concentrations of voriconazole in healthy and inflamed lung in rats, Antimicrobial Agents and Chemotherapy 53 (2009) 2684-2686.
9. S. Weiler, D. Fiegl, R. MacFarland, E. Stienecke, R. Bellmann-Weiler, S. Dunzendorfer, M. Joannidis, R. Bellmann, Human tissue distribution of voriconazole, Antimicrobial Agents and Chemotherapy 55 (2011) 925-928.
10. I.R. Camps, Risk factors for invasive fungal infections in haematopoietic stem cell transplantation, International Journal of Antimicrobial Agents 32 (Suppl. 2) (2008) S119-S123.
11. D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, J. Fishman, M. Pfaller, C. Chang, K. Webster, K. Marr, Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry, Clinical Infectious Diseases 48 (2009) 265-273.
12. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann, W.V. Kern, K.A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R.H. Rubin, J.R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P.H. Chandrasekar, M.R. Hodges, H.T. Schlamm, P.F. Troke, B. de Pauw, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, New England Journal of Medicine 347 (2002) 408-415. (Pubitemid 34851833)
13. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, V.A. Morrison, B.H. Segal, W.J. Steinbach, D.A. Stevens, J.A. van Burik, J.R. Wingard, T.F. Patterson, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clinical Infectious Diseases 46 (2008) 327-360. (Pubitemid 351265310)
14. R. Hyland, B.C. Jones, D.A. Smith, Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole, Drug Metabolism and Disposition 31 (2003) 540-547. (Pubitemid 36444162)
15. A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, O. Marchetti, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clinical Infectious Diseases 46 (2008) 201-211. (Pubitemid 351269158)
16. S. Trifilio, G. Pennick, J. Pi, J. Zook, M. Golf, K. Kaniecki, S. Singhal, S. Williams, J. Winter, M. Tallman, L. Gordon, O. Frankfurt, A. Evens, J. Mehta, Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients, Cancer 109 (2007) 1532-1535.
17. J.A. Tolman, N.A. Nelson, Y.J. Son, S. Bosselmann, N.P. Wiederhold, J.I. Peters, J.T. McConville, R.O. Williams, Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution, European Journal of Pharmaceutics and Biopharmaceutics 72 (2009) 199-205.
18. J.A. Tolman, N.P. Wiederhold, J.T. McConville, L.K. Najvar, R. Bocanegra, J.I. Peters, J.J. Coalson, J.R. Graybill, T.F. Patterson, R.O. Williams, Inhaled voriconazole for prevention of invasive pulmonary aspergillosis, Antimicrobial Agents and Chemotherapy 53 (2009) 2613-2615.
19. A.H. Chow, H.H. Tong, P. Chattopadhyay, B.Y. Shekunov, Particle engineering for pulmonary drug delivery, Pharmaceutical Research 24 (2007) 411-437. (Pubitemid 46295160)
20. H.K. Chan, N.Y. Chew, Novel alternative methods for the delivery of drugs for the treatment of asthma, Advanced Drug Delivery Reviews 55 (2003) 793-805. (Pubitemid 36776794)
21. Bhavna, F.J. Ahmad, G. Mittal, G.K. Jain, G. Malhotra, R.K. Khar, A. Bhatnagar, Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions, European Journal of Pharmaceutics and Biopharmaceutics 71 (2009) 282-291.
22. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. BenJebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer, Large porous particles for pulmonary drug delivery, Science 276 (1997) 1868-1871. (Pubitemid 27443665)
23. W. Yang, J.I. Peters, R.O. Williams, Inhaled nanoparticles - a current review, International Journal of Pharmaceutics 356 (2008) 239-247.
24. W. Yang, J. Tam, D.A. Miller, J. Zhou, J.T. McConville, K.P. Johnston, R.O. Williams, High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers, International Journal of Pharmaceutics 361 (2008) 177-188.
25. K.A. Overhoff, K.P. Johnston, J. Tam, J.D. Engstrom, R.O. Williams 3rd, Use of thin film freezing to enable drug delivery: a review, Journal of Drug Delivery Science and Technology 19 (2009) 89-98.
26. K.P. Johnston, J. Engstrom, J. Tam, A. Watts, Compositions and Methods of Making Brittle-matrix Particles through Blister Pack Freezing, US Patent Application 2010/0221343, 2010.
27. K.A. Overhoff, J.D. Engstrom, B. Chen, B.D. Scherzer, T.E. Milner, K.P. Johnston, R.O. Williams 3rd, Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs, European Journal of Pharmaceutics and Biopharmaceutics 65 (2007) 57-67. (Pubitemid 44827696)
28. United States Pharmacopeia, General Chapter 601: Aerosols, Nasal sprays, Metered-dose inhalers, and Dry powder inhalers, in: USP 32-NF 27, Rockville, MD, USA, 2010.
29. J.P. Mitchell, Practices of coating collection surfaces of cascade impactors: A survey of members of the European Pharmaceutical Aerosol Group (EPAG), in: Drug. Delivery (Ed.), To the Lungs-14, The Aerosol Society, London, UK, 2003, pp. 75-78.
30. Y.-J. Son, M. Horng, M. Copley, J.T. McConville, Optimization of an in vitro dissolution test method for inhalation formulations, Dissolution Technologies 17 (2010) 6-13.
31. J.W. Moore, H.H. Flanner, Mathematical comparison of dissolution profiles, Pharmaceutical Technology 20 (1996). 64, 66, 68, 72, 74.
32. FDA, US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997.
33. M. Morello, C.L. Krone, S. Dickerson, E. Howerth, W.A. Germishuizen, Y.L. Wong, D. Edwards, B.R. Bloom, M.K. Hondalus, Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies, Tuberculosis 89 (2009) 371-377.
34. I. Lutsar, S. Roffey, P. Troke, Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients, Clinical Infectious Diseases 37 (2003) 728-732. (Pubitemid 37100817)
35. A. Pascual, V. Nieth, T. Calandra, J. Bille, S. Bolay, L.A. Decosterd, T. Buclin, P.A. Majcherczyk, D. Sanglard, O. Marchetti, Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods, Antimicrobial Agents and Chemotherapy 51 (2007) 137-143. (Pubitemid 46047698)
36. N.A. Beinborn, H.L. Lirola, R.O. Williams III, Effect of process variables on morphology of voriconazole formulations produced by thin film freezing, The AAPS Journal 12 (2010).
37. SYMBICORT® prescribing information. 〈http://www1.astrazeneca-us. com/pi/symbicort/pdf〉 (cited 07.08.11).
38. FDA-CDER. 〈http://www.accessdata.fda.gov/scripts/cder/iig/index. cfm〉 (cited 07.08.11).
39. X.B. Liu, J.X. Ye, L.H. Quan, C.Y. Liu, X.L. Deng, M. Yang, Y.H. Liao, Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats, European Journal of Pharmaceutics and Biopharmaceutics 70 (2008) 845-852.
40. J.P. Latge, Aspergillus fumigatus and aspergillosis, Clinical Microbiology Reviews 12 (1999) 310-350.
41. J. Zhang, S. Ebbens, X. Chen, Z. Jin, S. Luk, C. Madden, N. Patel, C.J. Roberts, Determination of the surface free energy of crystalline and amorphous lactose by atomic force microscopy adhesion measurement, Pharmaceutical Research 23 (2006) 401-407. (Pubitemid 43237870)
42. B.C. Hancock, M. Parks, What is the true solubility advantage for amorphous pharmaceuticals?, Pharmaceutical Research 17 (2000) 397-404 (Pubitemid 30395293)
43. J.M. Tam, J.T. McConville, R.O. Williams 3rd, K.P. Johnston, Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution, Journal of Pharmaceutical Sciences 97 (2008) 4915-4933.
44. W. Yang, K.P. Johnston, R.O. Williams 3rd, Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats, European Journal of Pharmaceutics and Biopharmaceutics 75 (2010) 33-41.
45. R.J. Altiere, D.C. Thompson, Physiology and pharmacology of the airways, in: A.J. Hickey (Ed.), Inhalation Aerosols: Physical and Biological Basis for Therapy, Informa Healthcare, New York, 2007, pp. 83-126.